The FOSSIL Study: FLAG or standard 7+ 3 induction therapy in secondary acute myeloid leukemia
V Vulaj, AJ Perissinotti, JR Uebel, VR Nachar… - Leukemia research, 2018 - Elsevier
Patients with secondary acute myeloid leukemia (sAML) have poor outcomes, with CR/CRi
rates of 25–35% with standard 7+ 3 induction chemotherapy, while single center non …
rates of 25–35% with standard 7+ 3 induction chemotherapy, while single center non …
Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG
The 5-year overall survival (OS) in patients≥ 60 years old with acute myeloid leukemia
(AML) remains< 10%. Clofarabine-based induction (CLO) provides an alternative to low …
(AML) remains< 10%. Clofarabine-based induction (CLO) provides an alternative to low …
Quality and safety in the literature: November 2020
J Uebel, A Gupta, N Houchens - BMJ Quality & Safety, 2020 - qualitysafety.bmj.com
Quality and safety in the literature: November 2020 | BMJ Quality & Safety Skip to main content
Viewing from: Google Indexer BMJ Journals Subscribe Log In More Log in via Institution Log in …
Viewing from: Google Indexer BMJ Journals Subscribe Log In More Log in via Institution Log in …